Portfoliotracker

Allogene Therapeutics, Inc.

ALLO · NASDAQGS · Healthcare Biotechnology 0/100 E

0,807 $
▼ −0,032 (−3,78 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 11:58
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score0 / 100 Market cap279 mil. $ P/E– Forward P/E-1,3 P/S– P/B0,7 EV/EBITDA– Dividend yield– FCF yield-38,96 % EPS-0,61 $ Net margin0,0 % Return on equity-49,3 % Beta0,78 Debt / equity0,20
52-week range 0,77 to 4,46
3-month average volume7,5 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Employees
150
Country
United States
Fiscal year end
31. 12.
Data since
11. 10. 2018

Explore further

Similar companies FATEAUTLDNLIARVN

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account